Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Industry-partnered Collaborative Research

Université de Montréal

$116,000.00

Exploring GPCR functional selectivity for anti-inflammatory drugs

EF 2013-14

Résumé
The present proposal aims at characterizing the mechanism of action of novel anti-inflammatory drug candidates. These drug candidates target as their site of action a member of a large family of membrane proteins known as G protein-coupled receptors (GPCRs). More specifically, they target a subclass of this family that are activated by proteases, such as trypsin, that play important roles in many physiological processes. One of these receptors, the protease-activated receptor type-2 (PAR-2), is believed to be involved in the development of various inflammatory diseases. Scientists at Vertex Pharmaceuticals have discovered molecules targeting the PAR-2 receptor for the development of new drugs for the treatment of inflammatory bowel disease. These new drug candidates have unique properties that are in line with the recently emerging concept that rather than functioning as toggle switches that can turn pre-selected linear signalling cascades "on" or "off", GPCRs are more akin to signalling hubs that can regulate alternative subsets of signalling pathways. This concept, known as ligand-biased signalling or functional selectivity, raises the question of what are the most pertinent signalling pathways that should be targeted for therapeutic efficacy and reciprocally that should be avoided to prevent undesirable effects. The laboratory of the applicant has played a central role in these concepts and has generated novel tools to monitor functional selectivity. This project aims at monitoring multiple signalling pathways in living cells to identify which pathways are important for the therapeutically relevant action of drugs targeting PAR-2. In addition to providing a streamlined profiling platform for rapid structure activity relationship (SAR) studies to identify the best PAR-2 ligands, this study will allow to characterize the mechanism of action of the PAR-2 modulators developed by Vertex pharmaceutical and should help the development of novel anti-inflammatory drugs.
Programme
Operating Grant: Industry-partnered Collaborative Research
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
306304
Name
Bouvier Michel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Vertex Pharmaceuticals (Canada) Inc. (Laval, Québec); Vertex Pharmaceuticals (Canada) Inc. (Laval, Québec)
Instname2
Genetics
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Exploring GPCR functional selectivity for anti-inflammatory drugs
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$116,000
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research
Keyworddelim
Bioluminescence Resonance Energy Transfer; Biosensors; Functional Selectivity; G Protein-Coupled Receptors; Inflamatory Chemokines; Inflammatory Diseases; Protease-Activated Receptor
Abstract
The present proposal aims at characterizing the mechanism of action of novel anti-inflammatory drug candidates. These drug candidates target as their site of action a member of a large family of membrane proteins known as G protein-coupled receptors (GPCRs). More specifically, they target a subclass of this family that are activated by proteases, such as trypsin, that play important roles in many physiological processes. One of these receptors, the protease-activated receptor type-2 (PAR-2), is believed to be involved in the development of various inflammatory diseases. Scientists at Vertex Pharmaceuticals have discovered molecules targeting the PAR-2 receptor for the development of new drugs for the treatment of inflammatory bowel disease. These new drug candidates have unique properties that are in line with the recently emerging concept that rather than functioning as toggle switches that can turn pre-selected linear signalling cascades "on" or "off", GPCRs are more akin to signalling hubs that can regulate alternative subsets of signalling pathways. This concept, known as ligand-biased signalling or functional selectivity, raises the question of what are the most pertinent signalling pathways that should be targeted for therapeutic efficacy and reciprocally that should be avoided to prevent undesirable effects. The laboratory of the applicant has played a central role in these concepts and has generated novel tools to monitor functional selectivity. This project aims at monitoring multiple signalling pathways in living cells to identify which pathways are important for the therapeutically relevant action of drugs targeting PAR-2. In addition to providing a streamlined profiling platform for rapid structure activity relationship (SAR) studies to identify the best PAR-2 ligands, this study will allow to characterize the mechanism of action of the PAR-2 modulators developed by Vertex pharmaceutical and should help the development of novel anti-inflammatory drugs.
Competitiondate
201403
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Bouvier, Michel
Approvedterm
2 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $116,000~ $0~